Tvardi Therapeutics Inc. TVRD 深 沪
已收盘 07-02 16:00:00 美东时间
2.02
+0.070
+3.59%
华盛通- 最 高2.08
- 今 开1.93
- 成交量 11.21万股
- 最 低 1.9101
- 昨 收 1.95
- 总市值 1895.03万
- 52周最高 43.65
- 市盈率 静 --
- 换手率 1.20%
- 52周最低 1.50
- 委 比 -31.39%
- 总股本 938.13万
- 历史最高 1067.292
- 量 比 0.08
- 振 幅 8.71%
- 历史最低 1.50
- 每 手 1
- 风险率 12.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Universe Pharmaceuticals Shares Are Trading Higher By Around 228%; Here Are 20 Stocks Moving Premarket
Shares of Universe Pharmaceuticals Inc (NASDAQ:UPC) rose sharply in pre-market trading after the company announced it will acquire Best Praise International for $10.75 million. Universe Pharmaceuticals shares jumped 228.4% to $9.72 in pre-market trading. Here are some other stocks moving in pre-mark...
06-29 19:03
美股夜盘 | Tvardi Therapeutics Inc.涨22.67%，最新股价1.84美元
Tvardi Therapeutics Inc.涨22.67%，报1.84美元
06-29 08:20
美股夜盘 | 大自然药业涨187.16%，Decoy Therapeutics Inc.涨20.51%
LiveWire涨-10.87%；Pyxis Tankers, Inc.涨-9.05%；Cybin, Inc.涨-8.95%
06-29 08:05
美股大行评级 | 存储再获看多！美光、闪迪、西部数据获机构上调目标价；次新股Cerebras、Blackstone、EagleRock获多家机构首予买入平均
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.25美元升至5.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9美元升至9.25美元
06-09 11:33
HC Wainwright & Co. Initiates Coverage On Tvardi Therapeutics with Buy Rating, Announces Price Target of $9
HC Wainwright & Co. analyst Sara Nik initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Buy rating and announces Price Target of $9.
06-08 18:40
Tvardi Therapeutics Q1 EPS $(0.73) Beats $(0.74) Estimate
Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.74) by 1.35 percent. This is a 77.33 percent increase over losses of $(3.22) per share
05-08 19:11
Tvardi Therapeutics Files Prospectus For Offering $200M Mixed Shelf
https://www.sec.gov/Archives/edgar/data/1346830/000110465926054113/tm2613101-1_s3.htm
05-02 04:11
美股大行评级 | 大摩上调Lumentum目标价从595美元升至710美元；康宁、道富银行、Ally Financial获多家机构上调目标价
今日重点评级关注：Canaccord Genuity：维持Vertical Aerospace"买入"评级，目标价从9.5美元升至10.5美元；Canaccord Genuity：维持AtaiBeckley Inc."买入"评级，目标价从14美元升至15美元
04-21 11:25
Barclays Downgrades Tvardi Therapeutics to Underweight, Lowers Price Target to $3
Barclays analyst Etzer Darout downgrades Tvardi Therapeutics (NASDAQ:TVRD) from Equal-Weight to Underweight and lowers the price target from $4 to $3.
04-20 21:15
美股大行评级 | 绩后爆锤！耐克遭10家大行集体下调目标价；NCNO、RH、艾默生电气等也遭大行下调目标价
今日重点评级关注：Canaccord Genuity：维持Generac控股"买入"评级，目标价从275美元升至300美元；Oppenheimer：维持Biogen"跑赢大市"评级，目标价从250美元升至275美元
04-02 16:17
